t
Shield Therapeutics plc announced on 18 June 2026 the voting results for its 2026 Annual General Meeting. All 14 proposed resolutions were passed, with resolutions 1 to 12 passing as ordinary resolutions and 13 and 14 as special resolutions. The Company reported 1,069,524,125 shares in issue.
| Date | 18 Jun 2026 |
| Time | 16:20:59 |
| Category | AGMs and other meetings |
| ID | 9038I |
Shield Therapeutics plc
("Shield" or the "Company" or the "Group")
Results of 2026 Annual General Meeting
London, UK, 18 June 2026: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company specialising in iron deficiency with or without anemia ("ID/IDA"), announces the voting results for each resolution set out in the Notice of Annual General Meeting 2026. The Board reports that all resolutions were passed: 1 to 12 passed as ordinary resolutions and 13 and 14 passed as special resolutions.
The following table shows the votes cast on each resolution:
|
|
VOTES |
% |
VOTES AGAINST |
% |
WITHHELD VOTES |
|
Resolution 1 |
663,423,759 |
99.99% |
83,973 |
0.01% |
612,706 |
|
Resolution 2 |
663,165,096 |
99.96% |
259,840 |
0.04% |
695,502 |
|
Resolution 3 |
662,822,843 |
99.91% |
602,093 |
0.09% |
695,502 |
|
Resolution 4 |
663,131,934 |
99.96% |
267,835 |
0.04% |
720,669 |
|
Resolution 5 |
662,884,358 |
99.92% |
540,585 |
0.08% |
695,495 |
|
Resolution 6 |
663,146,757 |
99.96% |
253,012 |
0.04% |
720,669 |
|
Resolution 7 |
662,771,376 |
99.91% |
628,393 |
0.09% |
720,669 |
|
Resolution 8 |
663,346,163 |
99.97% |
189,245 |
0.03% |
585,030 |
|
Resolution 9 |
661,191,218 |
99.65% |
2,342,764 |
0.35% |
586,456 |
|
Resolution 10 |
660,806,346 |
99.56% |
2,944,366 |
0.44% |
369,726 |
|
Resolution 11 |
660,769,857 |
99.55% |
2,978,561 |
0.45% |
372,020 |
|
Resolution 12 |
658,773,200 |
99.24% |
5,058,591 |
0.76% |
288,647 |
|
Resolution 13 |
658,492,989 |
99.21% |
5,225,392 |
0.79% |
402,057 |
|
Resolution 14 |
658,549,598 |
99.26% |
4,920,741 |
0.74% |
650,099 |
Notes:
1. Number of shares in issue 1,069,524,125.
2. Details of the votes received on the resolutions are available on the Company's website:
https://shieldtherapeutics.com/financials.
3. Shield Therapeutics plc LEI: 213800G74QWY15FC3W71.
For further information please contact:
|
Shield Therapeutics plc |
|
|
Anders Lundstrom, CEO Stephanie Hicks, Investor Relations |
+44 (0) 191 511 8500 |
|
Nominated Adviser and Joint Broker |
|
|
Peel Hunt LLP |
|
|
James Steel |
+44 (0)20 7418 8900 |
|
|
|
|
Joint Broker Cavendish Ltd Geoff Nash/ Isaac Hooper/Nigel Birks/Harriet Ward |
+44 (0)20 7220 0500 |
|
|
|
|
|
|
About Iron Deficiency and ACCRUFeR®/FeRACCRU®
Clinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR® has the potential to meet an important unmet medical need for both physicians and patients and is now the leading #1 branded prescription oral iron the market today (data source - IQVIA Xponent PlanTrak).
ACCRUFeR®/FeRACCRU® (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA. The drug has a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFeR®/FeRACCRU®, including the product label, can be found at: www.accrufer.com and www.feraccru.com.
About Shield Therapeutics plc
Shield is a commercial stage specialty pharmaceutical company that delivers ACCRUFeR®/FeRACCRU® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched ACCRUFeR® in the U.S. to include pediatric patients 10 years of age and older with an exclusive, multi-year collaboration agreement with Viatris. Outside of the U.S., the Company has licensed the rights to five specialty pharmaceutical companies. FeRACCRU® is commercialised in the UK and European Union by Norgine B.V., to include pediatric patients 12 years of age and older and also have marketing rights in Australia and New Zealand. FeRACCRU® is also commercialised in Canada by Kye Pharmaceuticals Inc. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of ACCRUFeR®/FeRACCRU® in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea, and with Medleap Pharma Company Limited, a subsidiary of VITAL-NET Inc. for Japan.
ACCRUFeR®/FeRACCRU® has patent coverage until the mid-2030s.
ACCRUFeR®/FeRACCRU® are registered trademarks of Shield Therapeutics.